罗氏董事长仍预计诊断产品将受到美国关税的冲击

Core Viewpoint - Roche Group anticipates that its agreement with the U.S. government will protect its pharmaceuticals from the current round of import tariffs, but its diagnostics division may still face risks after the initial 150-day period due to potential new tariffs [1] Group 1 - Roche's diagnostics division is projected to generate sales close to 14 billion Swiss francs in 2025 [1] - A significant portion of Roche's tests and instruments are exported to the U.S. from Switzerland and other European countries [1]